Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chunghwa Chemical Synthesis & Biotech Co's EBIT per Share for the
three
months ended in Dec. 2025 was NT$-2.34.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-4.31.
During the past 12 months, the average EBIT per Share Growth Rate of Chunghwa Chemical Synthesis & Biotech Co was -5188.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Chunghwa Chemical Synthesis & Biotech Co was 145.50% per year. The lowest was -73.10% per year. And the median was -0.30% per year.
TPE:1762's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.5 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Chunghwa Chemical Synthesis & Biotech Co EBIT per Share Related Terms
Chunghwa Chemical Synthesis & Biotech Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chunghwa Chemical Synthesis & Biotech Co EBIT per Share Chart
Chunghwa Chemical Synthesis & Biotech Co Annual Data
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-4.31
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) has a EBIT per Share of NT$-4.31 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. According to the industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #999999 out of 1173 companies in the Biotechnology industry.
Is Chunghwa Chemical Synthesis & Biotech Co's EBIT per Share too high?
Chunghwa Chemical Synthesis & Biotech Co's current EBIT per Share is NT$-4.31. Based on the distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #999999 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chunghwa Chemical Synthesis & Biotech Co has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chunghwa Chemical Synthesis & Biotech Co's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #999999 out of 1173 companies for EBIT per Share. This places Chunghwa Chemical Synthesis & Biotech Co in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chunghwa Chemical Synthesis & Biotech Co's current EBIT per Share is NT$-4.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chunghwa Chemical Synthesis & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) is currently considered Fairly Valued. The stock's GF Value™ is NT$38.43, compared to a current price of NT$34.80 — trading 9.4% below its estimated fair value. The current EBIT per Share is NT$-4.31. Chunghwa Chemical Synthesis & Biotech Co's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Chunghwa Chemical Synthesis & Biotech Co (TPE:1762), the current EBIT per Share is NT$-4.31 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Overvalued in 2026?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co stock appears to be undervalued.
The current stock price of NT$34.80 is trading 9.4% below its estimated GF Value™ of NT$38.43.
GuruFocus considers Chunghwa Chemical Synthesis & Biotech Co to be Fairly Valued.
Key valuation signals for TPE:1762:
EBIT per Share: NT$-4.31
GF Value™: NT$38.43 vs. price of NT$34.80 (9.4% below fair value)
No single metric tells the full story. See the TPE:1762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chunghwa Chemical Synthesis & Biotech Co Business Description
Chunghwa Chemical Synthesis & Biotech Co Ltd is engaged in the research, development, manufacturing, and sales of pharmaceutical products. Geographically, it derives a majority of its revenue from the United States and also has a presence in Taiwan. Its product portfolio comprises pain management, antifungal, immunosuppressant, oncology, Cardiovascular, Peptide Drugs, and Others.
59GF Score
Get the complete analysis for TPE:1762
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1762 has been successfully added to your 
